Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remdesivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remdesivir SCHEMBL31156820 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712238 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712227 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL22143154 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL23685886 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712269 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494884 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494885 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24611640 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL20500116 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | TMPRSS2 355/4885CYP3A4 3112/4885CYP2C9 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.